Product Description
AVE9633 comprises the huMy9-6 antibody, which targets the CD33 antigen found on acute myeloid leukemia cells, and the potent cell-killing agent DM4.
Mechanisms of Action: CD33 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| TED10219 | P1 |
Terminated |
Acute Myeloid Leukemia |
2008-08-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|